Last updated 30 hours ago
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
276 patients around the world
Available in Chile
AbbVie
3Research sites
276Patients around the world
This study is for people with
Crohn's disease
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Biopsy-confirmed diagnosis of CD for at least 3 months prior to Baseline.Participant meets the following disease activity criteria.Moderate to severe CD as assessed by CDAI.Endoscopic evidence of mucosal inflammation as documented by a SES-CD.Participant has demonstrated intolerance, loss of response or inadequate response to conventional or advanced therapies for CD.
- Participants with a current diagnosis of ulcerative colitis or indeterminate colitis.Participants with unstable doses of concomitant Crohn's disease therapy.Participants with prior exposure to p19 inhibitors.Participants with complications of Crohn's disease.Participants having an ostomy or ileoanal pouch.
Sites
Clínica Dermacross S.A. - Vitacura - Santiago
Recruiting
Clínica Universidad de los Andes
Recruiting
Espacio EME
Recruiting
StudyRisa CD SubQ
SponsorAbbVie
Study typeInterventional
Conditions
Crohn's disease
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06063967
